Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
61
BDX Quote, Financials, Valuation and Earnings
Last price:
$196.30
Seasonality move
:
6.06%
Day range:
$194.87 - $197.24
52-week range:
$162.29 - $251.99
Dividend yield:
2.12%
P/E ratio:
33.68x
P/S ratio:
2.59x
P/B ratio:
2.21x
Volume:
1M
Avg. volume:
2.2M
1-year change:
-13.94%
Market cap:
$56B
Revenue:
$21.8B
EPS (TTM):
$5.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$5.5B | $3.37 | -0.31% | 169.42% | $204.83 |
|
ABT
Abbott Laboratories
|
$11.2B | $1.20 | 7.51% | -71.7% | $144.43 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.80 | 15.97% | 105.65% | $125.86 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.77 | 8.96% | 16.17% | $291.80 |
|
SOLV
Solventum Corp.
|
$1.9B | $1.48 | -5.45% | 768.77% | $85.64 |
|
WST
West Pharmaceutical Services, Inc.
|
$760M | $1.65 | 6.25% | 3.35% | $345.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$196.33 | $204.83 | $56B | 33.68x | $1.05 | 2.12% | 2.59x |
|
ABT
Abbott Laboratories
|
$124.84 | $144.43 | $217.1B | 15.66x | $0.59 | 1.89% | 4.98x |
|
BSX
Boston Scientific Corp.
|
$96.06 | $125.86 | $142.4B | 51.38x | $0.00 | 0% | 7.41x |
|
RMD
ResMed, Inc.
|
$244.76 | $291.80 | $35.7B | 25.05x | $0.60 | 0.92% | 6.85x |
|
SOLV
Solventum Corp.
|
$80.46 | $85.64 | $14B | 9.26x | $0.00 | 0% | 1.67x |
|
WST
West Pharmaceutical Services, Inc.
|
$274.30 | $345.71 | $19.7B | 40.63x | $0.22 | 0.31% | 6.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.495 | 37.48% | 0.47x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.345 | 8.31% | 0.81x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
SOLV
Solventum Corp.
|
50.75% | 0.962 | 40.57% | 0.94x |
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.397 | 1.61% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
Becton, Dickinson & Co. vs. Competitors
-
Which has Higher Returns BDX or ABT?
Abbott Laboratories has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 14.07%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About BDX or ABT?
Becton, Dickinson & Co. has a consensus price target of $204.83, signalling upside risk potential of 4.33%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.69%. Given that Abbott Laboratories has higher upside potential than Becton, Dickinson & Co., analysts believe Abbott Laboratories is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 ABTAbbott Laboratories15 7 0 -
Is BDX or ABT More Risky?
Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock BDX or ABT?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or ABT?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Becton, Dickinson & Co.'s net income of $493M is lower than Abbott Laboratories's net income of $1.6B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.68x while Abbott Laboratories's PE ratio is 15.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.59x versus 4.98x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M ABTAbbott Laboratories4.98x 15.66x $11.4B $1.6B
-
Which has Higher Returns BDX or BSX?
Boston Scientific Corp. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 14.91%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About BDX or BSX?
Becton, Dickinson & Co. has a consensus price target of $204.83, signalling upside risk potential of 4.33%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Boston Scientific Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 BSXBoston Scientific Corp.25 2 0 -
Is BDX or BSX More Risky?
Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.
-
Which is a Better Dividend Stock BDX or BSX?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or BSX?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Becton, Dickinson & Co.'s net income of $493M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.68x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.59x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M BSXBoston Scientific Corp.7.41x 51.38x $5.1B $755M
-
Which has Higher Returns BDX or RMD?
ResMed, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 26.1%. Becton, Dickinson & Co.'s return on equity of 6.6% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About BDX or RMD?
Becton, Dickinson & Co. has a consensus price target of $204.83, signalling upside risk potential of 4.33%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that ResMed, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe ResMed, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 RMDResMed, Inc.8 7 1 -
Is BDX or RMD More Risky?
Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock BDX or RMD?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or RMD?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Becton, Dickinson & Co.'s net income of $493M is higher than ResMed, Inc.'s net income of $348.5M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.68x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.59x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M RMDResMed, Inc.6.85x 25.05x $1.3B $348.5M
-
Which has Higher Returns BDX or SOLV?
Solventum Corp. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 60.4%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About BDX or SOLV?
Becton, Dickinson & Co. has a consensus price target of $204.83, signalling upside risk potential of 4.33%. On the other hand Solventum Corp. has an analysts' consensus of $85.64 which suggests that it could grow by 6.43%. Given that Solventum Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Solventum Corp. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 SOLVSolventum Corp.3 7 1 -
Is BDX or SOLV More Risky?
Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDX or SOLV?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or SOLV?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Becton, Dickinson & Co.'s net income of $493M is lower than Solventum Corp.'s net income of $1.3B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.68x while Solventum Corp.'s PE ratio is 9.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.59x versus 1.67x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M SOLVSolventum Corp.1.67x 9.26x $2.1B $1.3B
-
Which has Higher Returns BDX or WST?
West Pharmaceutical Services, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 17.41%. Becton, Dickinson & Co.'s return on equity of 6.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.
Company Gross Margin Earnings Per Share Invested Capital BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B -
What do Analysts Say About BDX or WST?
Becton, Dickinson & Co. has a consensus price target of $204.83, signalling upside risk potential of 4.33%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 26.04%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings BDXBecton, Dickinson & Co.3 9 0 WSTWest Pharmaceutical Services, Inc.11 3 0 -
Is BDX or WST More Risky?
Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.
-
Which is a Better Dividend Stock BDX or WST?
Becton, Dickinson & Co. has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDX or WST?
Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Becton, Dickinson & Co.'s net income of $493M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.68x while West Pharmaceutical Services, Inc.'s PE ratio is 40.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.59x versus 6.62x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDXBecton, Dickinson & Co.2.59x 33.68x $5.9B $493M WSTWest Pharmaceutical Services, Inc.6.62x 40.63x $804.3M $140M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
